Zacks.com on MSN1d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GSK's Blenrep treatment accepted for review by FDA
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
GlobalData on MSN3d
GSK eyes up combo approval for previously withdrawn myeloma drug
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Daily2d
USFDA accepts for review application for GSK Blenrep combinations for multiple myeloma treatment
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
GSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple Myeloma
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
London South East3d
Blenrep combinations accepted for US FDA review
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7 · If approved ...
Pharmabiz2d
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
London South East3d
GSK's Blenrep treatment accepted for review by FDA
(Sharecast News) - Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed or refractory multiple myeloma. The US Food and ...
MM&M1d
Rx Rundown: Roche, Sarepta Therapeutics, Merck and more
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
pharmaphorum1d
GSK hails survival data with revived myeloma drug Blenrep
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...